249 related articles for article (PubMed ID: 27561093)
1. Association of Matrix Metalloproteinases -7, -8 and -9 and TIMP -1 with Disease Severity in Acute Pancreatitis. A Cohort Study.
Nukarinen E; Lindström O; Kuuliala K; Kylänpää L; Pettilä V; Puolakkainen P; Kuuliala A; Hämäläinen M; Moilanen E; Repo H; Hästbacka J
PLoS One; 2016; 11(8):e0161480. PubMed ID: 27561093
[TBL] [Abstract][Full Text] [Related]
2. The imbalance between matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in acute pancreatitis.
Wereszczynska-Siemiatkowska U; Siemiatkowski A; Swidnicka-Siergiejko A; Mroczko B; Dabrowski A
Z Gastroenterol; 2015 Mar; 53(3):199-204. PubMed ID: 25775169
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
[TBL] [Abstract][Full Text] [Related]
4. Activated matrix metalloproteinase 8 in serum predicts severity of acute pancreatitis.
Turunen A; Kuuliala K; Kuuliala A; Tervahartiala T; Mustonen H; Puolakkainen P; Kylänpää L; Sorsa T
Pancreatology; 2021 Aug; 21(5):862-869. PubMed ID: 33846092
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases -8 and -9 and tissue inhibitor of metalloproteinase-1 in burn patients. A prospective observational study.
Hästbacka J; Fredén F; Hult M; Bergquist M; Wilkman E; Vuola J; Sorsa T; Tervahartiala T; Huss F
PLoS One; 2015; 10(5):e0125918. PubMed ID: 25945788
[TBL] [Abstract][Full Text] [Related]
6. Serum MMP-8 and TIMP-1 in critically ill patients with acute respiratory failure: TIMP-1 is associated with increased 90-day mortality.
Hästbacka J; Linko R; Tervahartiala T; Varpula T; Hovilehto S; Parviainen I; Vaara ST; Sorsa T; Pettilä V
Anesth Analg; 2014 Apr; 118(4):790-8. PubMed ID: 24651234
[TBL] [Abstract][Full Text] [Related]
7. Serum tissue-degrading proteinases and incident cardiovascular disease events.
Tuomainen AM; Kormi I; Havulinna AS; Tervahartiala T; Salomaa V; Sorsa T; Pussinen PJ
Eur J Prev Cardiol; 2014 Jul; 21(7):806-12. PubMed ID: 23079500
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases and their inhibitors in pediatric severe acute pancreatitis.
Vitale DS; Lahni P; Hornung L; Thompson T; Farrell PR; Lin TK; Nathan JD; Wong HR; Abu-El-Haija M
PLoS One; 2022; 17(2):e0261708. PubMed ID: 35157709
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of plasma MMP-8, MMP-9 and TIMP-1 identifies candidate cardiometabolic risk marker in metabolic syndrome: results from double-blinded nested case-control study.
Hoseini SM; Kalantari A; Afarideh M; Noshad S; Behdadnia A; Nakhjavani M; Esteghamati A
Metabolism; 2015 Apr; 64(4):527-38. PubMed ID: 25633268
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases during and outside of migraine attacks without aura.
Ashina M; Tvedskov JF; Lipka K; Bilello J; Penkowa M; Olesen J
Cephalalgia; 2010 Mar; 30(3):303-10. PubMed ID: 19614693
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases and their inhibitors in different acute stroke subtypes.
Vukasovic I; Tesija-Kuna A; Topic E; Supanc V; Demarin V; Petrovcic M
Clin Chem Lab Med; 2006; 44(4):428-34. PubMed ID: 16599837
[TBL] [Abstract][Full Text] [Related]
12. Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer.
Böckelman C; Beilmann-Lehtonen I; Kaprio T; Koskensalo S; Tervahartiala T; Mustonen H; Stenman UH; Sorsa T; Haglund C
BMC Cancer; 2018 Jun; 18(1):679. PubMed ID: 29929486
[TBL] [Abstract][Full Text] [Related]
13. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease.
Mäkitalo L; Rintamäki H; Tervahartiala T; Sorsa T; Kolho KL
Scand J Gastroenterol; 2012 Jul; 47(7):785-94. PubMed ID: 22519363
[TBL] [Abstract][Full Text] [Related]
14. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic value of neutrophil gelatinase-associated lipocalin, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinases-1 for sepsis in the Emergency Department: an observational study.
Wang M; Zhang Q; Zhao X; Dong G; Li C
Crit Care; 2014 Nov; 18(6):634. PubMed ID: 25407832
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis.
Lorente L; Martín MM; Labarta L; Díaz C; Solé-Violán J; Blanquer J; Orbe J; Rodríguez JA; Jiménez A; Borreguero-León JM; Belmonte F; Medina JC; Llimiñana MC; Ferrer-Agüero JM; Ferreres J; Mora ML; Lubillo S; Sánchez M; Barrios Y; Sierra A; Páramo JA
Crit Care; 2009; 13(5):R158. PubMed ID: 19799791
[TBL] [Abstract][Full Text] [Related]
17. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients.
Mroczko B; Groblewska M; Łukaszewicz-Zajac M; Bandurski R; Kedra B; Szmitkowski M
Clin Chem Lab Med; 2009; 47(9):1133-9. PubMed ID: 19728856
[TBL] [Abstract][Full Text] [Related]
18. Association of Plasma Matrix Metalloproteinase and Tissue Inhibitors of Matrix Metalloproteinase Levels With Adverse Treatment Outcomes Among Patients With Pulmonary Tuberculosis.
Kumar NP; Moideen K; Nancy A; Viswanathan V; Thiruvengadam K; Sivakumar S; Hissar S; Nair D; Banurekha VV; Kornfeld H; Babu S
JAMA Netw Open; 2020 Dec; 3(12):e2027754. PubMed ID: 33258908
[TBL] [Abstract][Full Text] [Related]
19. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q
Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301
[TBL] [Abstract][Full Text] [Related]
20. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
